ES3047101T3 - Prevention and/or treatment of neurodegenerative disease - Google Patents
Prevention and/or treatment of neurodegenerative diseaseInfo
- Publication number
- ES3047101T3 ES3047101T3 ES18725605T ES18725605T ES3047101T3 ES 3047101 T3 ES3047101 T3 ES 3047101T3 ES 18725605 T ES18725605 T ES 18725605T ES 18725605 T ES18725605 T ES 18725605T ES 3047101 T3 ES3047101 T3 ES 3047101T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- accordance
- zeaxanthin
- disease
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
| PCT/GB2018/051255 WO2019110951A1 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3047101T3 true ES3047101T3 (en) | 2025-12-03 |
Family
ID=60950313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18725605T Active ES3047101T3 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10835509B2 (enExample) |
| EP (2) | EP4599891A3 (enExample) |
| JP (1) | JP2021505527A (enExample) |
| KR (1) | KR20200095452A (enExample) |
| AU (1) | AU2018379644B2 (enExample) |
| BR (1) | BR112020005132A2 (enExample) |
| CA (1) | CA3071786C (enExample) |
| ES (1) | ES3047101T3 (enExample) |
| GB (2) | GB201720119D0 (enExample) |
| IE (1) | IE87241B1 (enExample) |
| MX (1) | MX2020002458A (enExample) |
| RU (1) | RU2020111305A (enExample) |
| SG (1) | SG11202000786RA (enExample) |
| WO (1) | WO2019110951A1 (enExample) |
| ZA (1) | ZA202000558B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
| US12076299B2 (en) | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
| TW202313075A (zh) * | 2021-05-17 | 2023-04-01 | 日商小野藥品工業股份有限公司 | 用於改善認知功能之組合物 |
| CN120417894A (zh) * | 2022-12-26 | 2025-08-01 | 三得利控股株式会社 | 脑神经细胞保护用组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| EP2219478B1 (en) * | 2007-12-17 | 2017-05-10 | Newtricious B.V. | Method of producing egg yolk based functional food product and products obtainable thereby |
| GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| ES2675905T3 (es) * | 2011-07-07 | 2018-07-13 | Howard Foundation Holdings Limited | Método para mejorar la discapacidad por deslumbramiento |
| DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
| GB201300055D0 (en) * | 2013-01-03 | 2013-02-20 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
| US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
| HK1211836A1 (en) * | 2013-03-28 | 2016-06-03 | Omniactive Health Technologies Limited | Neuroprotective effect of carotenoids in brain |
| WO2015005443A1 (ja) * | 2013-07-10 | 2015-01-15 | ライオン株式会社 | 内服組成物 |
| EP3419439B1 (en) * | 2016-02-22 | 2020-04-08 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 JP JP2020521460A patent/JP2021505527A/ja active Pending
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 EP EP25186112.6A patent/EP4599891A3/en active Pending
- 2018-05-10 ES ES18725605T patent/ES3047101T3/es active Active
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en not_active Ceased
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko active Pending
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 EP EP18725605.2A patent/EP3644979B1/en active Active
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE87241B1 (en) | 2021-07-07 |
| CA3071786A1 (en) | 2019-06-13 |
| WO2019110951A1 (en) | 2019-06-13 |
| US10835509B2 (en) | 2020-11-17 |
| AU2018379644A1 (en) | 2020-03-19 |
| KR20200095452A (ko) | 2020-08-10 |
| EP3644979B1 (en) | 2025-08-06 |
| AU2018379644B2 (en) | 2024-02-08 |
| GB201720119D0 (en) | 2018-01-17 |
| US20190167624A1 (en) | 2019-06-06 |
| RU2020111305A (ru) | 2022-01-10 |
| GB2568986B (en) | 2019-12-18 |
| BR112020005132A2 (pt) | 2020-09-15 |
| NZ761512A (en) | 2024-01-26 |
| JP2021505527A (ja) | 2021-02-18 |
| GB201807590D0 (en) | 2018-06-27 |
| ZA202000558B (en) | 2021-10-27 |
| GB2568986A (en) | 2019-06-05 |
| IE20180146A1 (en) | 2019-06-12 |
| CA3071786C (en) | 2023-11-14 |
| MX2020002458A (es) | 2020-07-20 |
| EP4599891A3 (en) | 2025-10-22 |
| EP3644979A1 (en) | 2020-05-06 |
| SG11202000786RA (en) | 2020-06-29 |
| EP4599891A2 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rautiainen et al. | Dietary supplements and disease prevention—a global overview | |
| Stringham et al. | Lutein across the lifespan: From childhood cognitive performance to the aging eye and brain | |
| Park et al. | Parenteral fish oil–containing lipid emulsions may reverse parenteral nutrition–associated cholestasis in neonates: a systematic review and meta-analysis | |
| ES3047101T3 (en) | Prevention and/or treatment of neurodegenerative disease | |
| ES2832734T3 (es) | Mejoras en el rendimiento visual o relacionadas con este | |
| Schalch et al. | Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin–the LUXEA (LUtein Xanthophyll Eye Accumulation) study | |
| Otaegui-Arrazola et al. | Diet, cognition, and Alzheimer’s disease: food for thought | |
| Bernstein et al. | The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders | |
| Mischoulon et al. | Docosahexanoic acid and ω-3 fatty acids in depression | |
| US20130108706A1 (en) | Dietary formulations | |
| RU2406411C1 (ru) | Долговременное питание для престарелых | |
| Demirel et al. | The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study | |
| Bowen et al. | Carotenoids in human nutrition | |
| Ferraz et al. | The antidepressant role of dietary long-chain polyunsaturated n-3 fatty acids in two phases in the developing brain | |
| Tan et al. | Roles of macular carotenoids in brain function throughout the lifespan: A review of recent research | |
| US20200197349A1 (en) | Cognitive function | |
| Partinen et al. | Nutrition, sleep and sleep disorders–relations of some food constituents and sleep | |
| Bone et al. | Efficacy of diacetate esters of macular carotenoids: effect of supplementation on macular pigment | |
| US20190307715A1 (en) | Prevention and/or treatment of neurodegenerative disease | |
| Takeda et al. | Effects of mayonnaise on postprandial serum lutein/zeaxanthin and β-carotene concentrations in humans | |
| Ulbricht | An evidence-based systematic review of lutein by the Natural Standard Research Collaboration | |
| Abreu-González et al. | Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products | |
| Galvin | Medical foods and dietary approaches in cognitive decline, mild cognitive impairment, and dementia | |
| HASBAL-CELIKOK | NUTRITIONAL SUPPLEMENTS FOR BRAIN HEALTH | |
| Harris et al. | 1 Age-Related Macular Degeneration |